Journal detail
Cerebrovascular Diseases
Cerebrovascular Diseases is a Q2 journal in SJR 2025 (best category) and Q3 in JCR 2025. Its Journal Impact Factor is 1.8. Web of Science lists it in SCIE.
- Publisher
- S. Karger AG
- Country
- Switzerland · Western Europe
- Type
- journal
- ISSN
-
1015977014219786
Integrated evaluation
Scopus side is Scimago SJR; WoS side is Master Journal List + JCR/JIF. Sources are matched on ISSN. WoS / JCR metrics are available for 1997 and later years only.
WoS / JCR data covers 1997 onward.
Scopus
Scopus · Scimago
- SJR 0,653
- Quartile Q2
- H-Index 126
- Cites/doc 2,28
- Docs (3y) 264
- Cites (3y) 596
Clarivate
Web of Science · JCR · 2025
- JCR Q Q3
- JIF 1,8
- 5Y JIF 2,2
- JCI 0,47
WoS indexes
- SCIE
Subject classification
Categories (SJR)
Areas
WoS categories
Yearly quartile comparison
Scimago (SJR) for all years; Clarivate (JCR / JIF / JCI) from 1997 onward. Latest year stays open; older years start collapsed.
WoS / JCR data covers 1997 onward.
| Year | SJR Q | JCR Q (1997+) | SJR | JIF (1997+) | 5Y JIF (1997+) | JCI (1997+) | JCI Q (1997+) | H-Index |
|---|---|---|---|---|---|---|---|---|
| 2025 | Q2 | Q3 | 0,653 | 1,8 | 2,2 | 0,47 | Q3 | 126 |
| 2024 | Q2 | Q3 | 0,689 | 1,5 | 2,2 | 0,49 | Q3 | 122 |
| 2023 | Q2 | Q3 | 0,7 | 2,2 | 2,5 | 0,58 | Q2 | 122 |
| 2022 | Q2 | Q2 | 0,757 | 2,9 | 3,2 | 0,61 | Q2 | 122 |
| 2021 | Q2 | Q3 | 0,834 | 3,1 | 3,6 | 0,61 | Q2 | 122 |
| 2020 | Q1 | Q3 | 1,221 | 2,8 | 3,4 | 0,71 | Q2 | 122 |
| 2019 | Q1 | Q2 | 1,168 | 2,7 | 3,1 | 0,77 | Q2 | 122 |
| 2018 | — | Q2 | — | 2,7 | 3,1 | 0,86 | Q1 | — |
| 2017 | Q1 | Q2 | 1,517 | 2,9 | 3,5 | 0,81 | Q2 | 122 |
| 2016 | Q1 | Q2 | 1,618 | 3 | 3,4 | — | — | 122 |
| 2015 | Q1 | Q1 | 1,69 | 3,4 | 3,3 | — | — | 122 |
| 2014 | Q1 | Q1 | 1,846 | 3,8 | 3,5 | — | — | 122 |
| 2013 | Q1 | Q1 | 1,848 | 3,7 | 3,5 | — | — | 122 |
| 2012 | Q1 | Q2 | 1,723 | 2,8 | 3,2 | — | — | 122 |
| 2011 | Q1 | Q2 | 1,645 | 2,7 | 2,8 | — | — | 122 |
| 2010 | Q1 | Q2 | 1,525 | 3 | 3 | — | — | 122 |
| 2009 | — | Q1 | — | 3,5 | 3,3 | — | — | — |
| 2008 | — | Q2 | — | 3 | 2,9 | — | — | — |
| 2007 | — | Q2 | — | 2,5 | 2,6 | — | — | — |
| 2006 | — | Q2 | — | 2 | — | — | — | — |
| 2005 | — | Q2 | — | 2,3 | — | — | — | — |
| 2004 | — | Q2 | — | 2,1 | — | — | — | — |
| 2003 | — | Q2 | — | 2 | — | — | — | — |
| 2002 | — | Q2 | — | 1,9 | — | — | — | — |
| 2001 | — | Q2 | — | 1,7 | — | — | — | — |
| 2000 | — | Q1 | — | 3 | — | — | — | — |
| 1999 | — | Q2 | — | 1,7 | — | — | — | — |
| 1998 | — | Q2 | — | 1,3 | — | — | — | — |
| 1997 | — | Q2 | — | 1,6 | — | — | — | — |
JCR category quartile history
JCR / JCI quartile by year and category. 1997 and later.
WoS / JCR data covers 1997 onward.
| Year | Category | Edition | JCR Q (1997+) | JCI Q (1997+) | Rank |
|---|---|---|---|---|---|
| 2025 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 213/296 |
| 2025 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 66/100 |
| 2024 | CLINICAL NEUROLOGY | SCIE | Q4 | Q3 | 215/286 |
| 2024 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q3 | 73/98 |
| 2023 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 156/280 |
| 2023 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 50/96 |
| 2022 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 116/212 |
| 2022 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 34/68 |
| 2021 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 126/212 |
| 2021 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 38/67 |
| 2020 | CLINICAL NEUROLOGY | SCIE | Q3 | Q3 | 133/208 |
| 2020 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | Q2 | 39/65 |
| 2019 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 98/204 |
| 2019 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 32/65 |
| 2018 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 96/199 |
| 2018 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q1 | 30/65 |
| 2017 | CLINICAL NEUROLOGY | SCIE | Q2 | Q2 | 81/197 |
| 2017 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | Q2 | 28/65 |
| 2016 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 71/194 |
| 2016 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 30/63 |
| 2015 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 54/193 |
| 2015 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 15/63 |
| 2014 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 38/192 |
| 2014 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 16/60 |
| 2013 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 41/194 |
| 2013 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 17/65 |
| 2012 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 66/193 |
| 2012 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 27/68 |
| 2011 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 73/192 |
| 2011 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 24/68 |
| 2010 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 58/185 |
| 2010 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/68 |
| 2009 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 35/167 |
| 2009 | PERIPHERAL VASCULAR DISEASE | SCIE | Q1 | — | 14/61 |
| 2008 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 41/156 |
| 2008 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/56 |
| 2007 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 49/146 |
| 2007 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 22/54 |
| 2006 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 68/147 |
| 2006 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 29/52 |
| 2005 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 52/148 |
| 2005 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 25/51 |
| 2004 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 51/140 |
| 2004 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 21/51 |
| 2003 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 50/135 |
| 2003 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/52 |
| 2002 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 52/138 |
| 2002 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 22/52 |
| 2001 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 46/136 |
| 2001 | PERIPHERAL VASCULAR DISEASE | SCIE | Q3 | — | 26/50 |
| 2000 | CLINICAL NEUROLOGY | SCIE | Q1 | — | 19/137 |
| 2000 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 13/45 |
| 1999 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 50/132 |
| 1999 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 20/44 |
| 1998 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 53/125 |
| 1998 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 19/39 |
| 1997 | CLINICAL NEUROLOGY | SCIE | Q2 | — | 38/107 |
| 1997 | PERIPHERAL VASCULAR DISEASE | SCIE | Q2 | — | 15/38 |
Frequently asked questions
Answers are generated from the Scimago (Scopus) and Journal Citation Reports (Web of Science) values on this page.
- Is Cerebrovascular Diseases a Q1, Q2, Q3 or Q4 journal? What is its quartile?
- Q2 in SJR 2025 (Scopus, best category). Q3 in JCR 2025 (Web of Science).
- Is Cerebrovascular Diseases indexed in Web of Science (SCIE, SSCI, AHCI, ESCI)?
- Yes. Web of Science lists it in SCIE.
- What is the impact factor of Cerebrovascular Diseases?
- Its Journal Impact Factor is 1.8 in JCR 2025. The five-year impact factor is 2.2.
- What are the SJR and h-index of Cerebrovascular Diseases?
- Its SJR is 0.653 in 2025. Its h-index is 126 (Scopus, Scimago).